| CTVA |
Report |
Operating EPS (2Q26) |
BEAT |
pred ~$2.35 vs. cons $2.23 |
HIGH |
| CTVA |
Report |
Net sales (2Q26) |
IN-LINE |
pred ~$6.65B vs. cons $6.61B |
MEDIUM |
| CTVA |
Report |
Operating EBITDA (2Q26) |
BEAT |
pred ~$2.32B vs. cons $2.25B |
MEDIUM |
| CTVA |
Guide |
FY26 Operating EPS guide |
BETTER |
guide ~$3.55-3.75 (raised low end/midpoint) vs. cons $3.63 (FY26) |
MEDIUM |
| CTVA |
Guide |
FY26 Operating EBITDA guide |
BETTER |
guide ~$4.10-4.25B vs. cons $4.13B (FY26) |
MEDIUM |
| CTVA |
Guide |
Separation / spin timing & framework |
UNCHANGED |
reaffirm Q4 2026 spin vs. Sept 15 2026 Investor Day (FY26) |
MEDIUM |
| CTVA |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.0% |
— |
MEDIUM |
| CTVA |
Return |
5-day cumulative residual |
-0.5% (FADE) |
Beat + modest FY raise is the base case, but the stock ran ~34% YTD and showed pre-earnings idiosyncratic strength (up while S&P fell into the print), so much is priced in. Out-period math limits upside: Q1 pulled seed volume forward (soft optical Q2/2H seed comps), CP pricing still negative, and a ~$40M 2H oil headwind plus LatAm/credit risk cap upward revisions. The raise mostly banks 1H beats rather than lifting 2H, so estimates don't rerate much and the initial pop gives back part of the gain — separation optionality (Sept 15 Investor Day) supports the floor but doesn't drive near-term numbers. |
LOW |